Benign prostatic hyperplasia: Natural evolution versus medical treatment

被引:0
|
作者
DaSilva, FC
机构
关键词
benign prostatic hyperplasia; alpha(1)-blockers; quality of life; epidemiology;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The epidemiology and natural evolution of benign prostatic hyperplasia (BPH) are important when considering the topic of natural evolution versus medical treatment, The incidence of BPH increases with age; it is thought that about 75 % of men over 50 years of age suffer from some symptoms commonly associated with BPH. There are also differences in the incidence of BPH between various racial and ethnic groups. For example, it is considerably less common amongst Japanese men compared with Caucasians. Evidence from prospective studies, retrospective studies and the placebo arms of randomised, controlled studies regarding the natural evolution of BPH suggests that a strategy of 'watchful waiting' may be considered as a treatment option as the majority of patients do not show a worsening of symptoms over time, However, the chance for improvement of symptoms and the degree of symptom improvement has been shown to be higher with alpha(1)-blocker therapy than with 'watchful waiting', as both symptoms and treatment have an impact on the patient's quality of life, there is now a strong case for involving the patient in making quality-of-life decisions based on his own preferences and attitudes.
引用
收藏
页码:34 / 37
页数:4
相关论文
共 50 条
  • [1] Treatment of Benign Prostatic Hyperplasia by Natural Drugs
    Csikos, Eszter
    Horvath, Adrienn
    Acs, Kamilla
    Papp, Nora
    Balazs, Viktoria Lilla
    Dolenc, Marija Sollner
    Kenda, Masa
    Kocevar Glavac, Nina
    Nagy, Milan
    Protti, Michele
    Mercolini, Laura
    Horvath, Gyorgyi
    Farkas, Agnes
    MOLECULES, 2021, 26 (23):
  • [2] Medicoeconomic aspects of benign prostatic hyperplasia medical treatment
    Lebdai, S.
    Azzouzi, A. R.
    Delongchamps, N. -B.
    Benchikh, A.
    Campeggi, A.
    Cornu, J. -N.
    Dumonceau, O.
    Faix, A.
    Fourmarier, M.
    Haillot, O.
    Lukacs, B.
    Mathieu, R.
    Misrai, V.
    Robert, G.
    de La Taille, A.
    Descazeaud, A.
    PROGRES EN UROLOGIE, 2016, 26 (02): : 129 - 136
  • [3] Recent progress in the medical treatment of benign prostatic hyperplasia
    Cornu, Jean-Nicolas
    Roupret, Morgan
    PROGRES EN UROLOGIE, 2007, 17 (05): : 1029 - 1032
  • [4] Medical treatment of benign prostatic hyperplasia and instrumental alternatives
    d'Urologie, Service
    E-MEMOIRES DE L ACADEMIE NATIONALE DE CHIRURGIE, 2005, 4 (01): : 4 - 7
  • [5] Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia
    Harkaway, R. C.
    Issa, M. M.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (03) : 204 - 214
  • [6] Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia
    R C Harkaway
    M M Issa
    Prostate Cancer and Prostatic Diseases, 2006, 9 : 204 - 214
  • [7] Treatment of Benign Prostatic Hyperplasia
    Pinheiro, Luis Campos
    Pisco, Joao Martins
    TECHNIQUES IN VASCULAR AND INTERVENTIONAL RADIOLOGY, 2012, 15 (04) : 256 - 260
  • [8] Natural history of benign prostatic hyperplasia
    Masumori, Naoya
    Fukuta, Fumimasa
    Tsukamoto, Taiji
    JOURNAL OF MENS HEALTH, 2011, 8 : S19 - S21
  • [9] The natural history of Benign Prostatic Hyperplasia
    Toksoz, Serdar
    Dirim, Ayhan
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2011, 10 (04): : 5 - 10
  • [10] The evolution of the use of the holmium laser for the treatment of benign prostatic hyperplasia
    Gilling, PJ
    Cass, CB
    Cresswell, MD
    Kennett, KM
    Mackey, M
    Fraundorfer, MR
    Kabalin, JN
    LASERS IN SURGERY: ADVANCED CHARACTERIZATION, THERAPEUTICS, AND SYSTEMS VII, PROCEEDINGS OF, 1997, 2970 : 448 - 451